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GONADAL GERM CELL TUMORS 
Akitoshi TAKIZAWA， Takeshi MIURA， Kiyoshi FUJINAMI and Yutaka OSADA 
The Department 01 Urology， Kanagawa Cancer Center 
Twenty-five patients with germ cell tumors who had marker-free residual masses after undergoing 
chemotherapy were followed for up to 10 years (median， 21months). The primary tumor sites were 
the gonads in 20 patients (6 seminomas [SGCTs] and 14 non-seminomatous germ cell tumors 
[NSGCTs]) and extra-gonadal regions in 5 patients (5 NSGCTs). All residual masses were observed 
in patients with SGCT. Residual masses that were 2 cm or less in size were left unresected， while 
masses that were 5 cm or more in size were resected in patients with NSGCT lesions. The 
management of other residual masses was decided based on the size， shrinkage， and pathological 
findings of the tumors. Residual masses were resected in six of the patients with gonadal NSGCTs. 
Recurrence occurred in one of the six patients with gonadal SGCTs (chemotherapy shrinkage; II 
cm to 3.5 cm) and three ofthe four cases with extra-gonadal NSGCTs (embryonal cel carcinoma: 3 cm 
to 1 cm， em bryonal cell carcinoma + york sac tumor: 5 cm to 4 cm， em bryonal cel carcinoma + chorio 
carcinoma; 4 cm to 1.2 cm). None of the patients with gonadal NSGCTs experienced a recurre恥 e.
Considering the pathologic diagnosis， shrinkage， and international germ cel consensus 
classification， unnecessary resections of residual masses that were less than 5 cm in size after 
chemotherapy for gonadal NSGCT should be avoided. However， residual masses in extra-gonadal 
NSGCTs should be resected. 




































248 泌尿紀要 51巻 4号 2005年
Table 1. Patient characteristics 
精巣 精巣外
NSGCT SGCT NSGCT 
経過観察 切除 経過観察 経過観察
症例数(奇形腫含む) 8 (1) 6 (4) 6 5 (I) 
年齢(歳) 34 (27-45) 34 (25-47) 36 (26-66) 28 (23-39) 
病期 stage 1 (再発) 2 
IGCCC Good 3 2 
Int 2 2 3 2 
por 2 3 
残存腫蕩径 (mm) 10 ( 2-30) 42 (24-130) 10 ( 3-40) 25 (10-40) 
縮小率(%) 68 (40-94) 48 (10-76) 75 (68-97) 67 (20-72) 
経過観察期間(月) 26 (13-81) 18 (11-81) 54 ( 3-114) 8 ( 3-122) 
IGCCC: International germ cel consensus c1assification. Good: Good prognosis， 
Int: Intermediate prognosis， Por: poor prognosis. 
Table 2. In 6 of the patients with gonadal NSGCTs， residual masses were resected 
方針 理由 原発組織 切除臓器 病理 切除後残存腫蕩
全切除困難 Y+C+imT 肺 (7cm) N/F 肺
最大腫蕩切除 全切除困難 E RPLN (5.5 cm) mT 肺+縦隔 LN
切除容易 Y 肺 (2.4cm) N/F RPLN 
切除容易 S+E+imT 肺 (2.7cm) imT なし
会腫蕩切除 化療中増大 E+imT RPLN (2.8 cm) mT なし
大きい imT RPLN (13 cm) mT+imT なし
S: seminoma， E: embryonal carcinoma， Y: york sac tumor， mT: mature teratoma， imT: immature 

































































































Fig. 1. The size and shrinkage of residual masses. X: recurrence， 0: operation. imT: im-









率)は， SGCTの再発例は 1cmから 3.5cm 
(68.2%) ，精巣外原発 NSGCTの再発した 3例は 3











87 % 1)， NSGCTで37-87%5)の残存腫場は壊死組織
に対する不要な手術になるといわれる. Position 
































































は欧米6施設による Re-analysisof Histology in Tes-
ticular Cancer (以下 ReHIT)研究で， 544例の後腹
膜リンパ節転移の残存腫蕩切除結果をロジスティック
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